Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADE: Plozasiran in Familial Chylomicronemia Syndrome
NCT05089084Phase 3Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Apr 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 21
01
Overview
A Phase 3 trial of plozasiran in familial chylomicronemia syndrome (FCS), sponsored by Arrowhead Pharmaceuticals. Started Dec 2021; status: completed.
02
Drugs
plozasiran
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT05089084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089084.